FFO
AXSM icon

Fiduciary Family Office’s Axsome Therapeutics AXSM Stock Holding History

Fiduciary Family Office’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362K Sell
1,477
-192
-12% -$41.6K 0.09% 138
2026
Q1 		$282K Sell
1,669
-614
-27% -$106K 0.08% 152
2025
Q4 		$417K Sell
2,283
-387
-14% -$54K 0.12% 120
2025
Q3 		$324K Buy
+2,670
New +$301K 0.09% 146

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Fiduciary Family Office's AXSM Position: Q2 2026 in Review

Fiduciary Family Office reduced its Axsome Therapeutics (AXSM) stake by 12% in Q2 2026, selling an estimated $41.6K and leaving 1,477 shares worth $362K. The position accounts for 0.09% of the portfolio, ranked #138.

Fiduciary Family Office first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. The position peaked at $417K in Q4 2025. 242 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Fiduciary Family Office held 1,477 shares of Axsome Therapeutics worth $362K as of Q2 2026.
  • Fiduciary Family Office sold 192 Axsome Therapeutics shares in Q2 2026, an estimated $41.6K.
  • Axsome Therapeutics made up 0.09% of Fiduciary Family Office's portfolio in Q2 2026, its #138 holding.
  • Fiduciary Family Office first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Fiduciary Family Office's Axsome Therapeutics position peaked at $417K in Q4 2025.
  • 242 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Fiduciary Family Office's 13F filing for Q2 2026, filed 5 Aug 2026.